Amrita Y Krishnan

6PUBLICATIONS
60CO-AUTHORS
Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)BiomechanicsGene and molecular therapyMedical mycologyHaematological tumours
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|Sep 02, 2026
Teclistamab and Daratumumab Immune-Based Doublet Therapy for Relapsed/Refractory Multiple Myeloma: the TRIMM-2 Study.

|May 21, 2026
mHealth-Supported Exercise Rehabilitation to Reverse Frailty After Autologous Transplantation in Multiple Myeloma: Randomized Controlled Trial.

|Aug 22, 2024
Efficacy and safety of teclistamab in patients with relapsed/refractory multiple myeloma after BCMA-targeting therapies.

Cyrille Touzeau, Amrita Y Krishnan, Philippe Moreau

|May 03, 2024
Minimal Residual Disease Status in Multiple Myeloma 1 Year After Autologous Hematopoietic Cell Transplantation and Lenalidomide Maintenance Are Associated With Long-Term Overall Survival.

Marcelo C Pasquini, Paul K Wallace, Brent Logan

|Feb 23, 2024
A CD38-directed, single-chain T-cell engager targets leukemia stem cells through IFN-γ-induced CD38 expression.

Mariam Murtadha, Miso Park, Yinghui Zhu

|Jan 18, 2024
Cellular Mass Response to Therapy Correlates With Clinical Response for a Range of Malignancies.

Mark M Stevens, Robert J Kimmerling, Selim Olcum

Pageof 1

Frequent Collaborators

2 joint publications

Raluca I Verona

2 joint publications

Nizar J Bahlis

1 joint publications

Mark M Stevens

1 joint publications

Noopur Raje